Literature DB >> 23746190

Pharmacogenomic biomarkers for personalized medicine.

James J Chen1, Wei-Jiun Lin, Hung-Chia Chen.   

Abstract

Pharmacogenomics examines how the benefits and adverse effects of a drug vary among patients in a target population by analyzing genomic profiles of individual patients. Personalized medicine prescribes specific therapeutics that best suit an individual patient. Much current research focuses on developing genomic biomarkers to identify patients, to identify which patients would benefit from a treatment, have an adverse response, or no response at all, prior to treatment according to relevant differences in risk factors, disease types and/or responses to therapy. This review describes the use of the two personalized medicine biomarkers, prognostic and predictive, to classify patients into subgroups for treatment recommendation.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23746190     DOI: 10.2217/pgs.13.75

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN: 1462-2416            Impact factor:   2.533


  7 in total

1.  CYP2D6 genotype is not associated with survival in breast cancer patients treated with tamoxifen: results from a population-based study.

Authors:  D L Hertz; K M Kidwell; S G Hilsenbeck; S Oesterreich; C K Osborne; S Philips; C Chenault; R J Hartmaier; T C Skaar; M J Sikora; J M Rae
Journal:  Breast Cancer Res Treat       Date:  2017-07-20       Impact factor: 4.872

2.  A systematic review of miRNAs as biomarkers in osteoporosis disease.

Authors:  Mandana Hasanzad; Maryam Hassani Doabsari; Marzieh Rahbaran; Pantea Banihashemi; Fatemeh Fazeli; Mehrnoush Ganji; Shahrzad Manavi Nameghi; Negar Sarhangi; Shekoufeh Nikfar; Hamid Reza Aghaei Meybodi
Journal:  J Diabetes Metab Disord       Date:  2021-08-27

3.  A statistical perspective on baseline adjustment in pharmacogenomic genome-wide association studies of quantitative change.

Authors:  Hong Zhang; Aparna Chhibber; Peter M Shaw; Devan V Mehrotra; Judong Shen
Journal:  NPJ Genom Med       Date:  2022-06-09       Impact factor: 6.083

Review 4.  Diabetic retinopathy: variations in patient therapeutic outcomes and pharmacogenomics.

Authors:  Aniruddha Agarwal; Mohamed K Soliman; Yasir J Sepah; Diana V Do; Quan Dong Nguyen
Journal:  Pharmgenomics Pers Med       Date:  2014-12-12

5.  A composite model for subgroup identification and prediction via bicluster analysis.

Authors:  Hung-Chia Chen; Wen Zou; Tzu-Pin Lu; James J Chen
Journal:  PLoS One       Date:  2014-10-27       Impact factor: 3.240

6.  Precision Medicine Tools to Guide Therapy and Monitor Response to Treatment in a HER-2+ Gastric Cancer Patient: Case Report.

Authors:  Adriana Aguilar-Mahecha; Sarah Joseph; Luca Cavallone; Marguerite Buchanan; Urszula Krzemien; Gerald Batist; Mark Basik
Journal:  Front Oncol       Date:  2019-08-06       Impact factor: 6.244

7.  Pharmacogenomics polygenic risk score for drug response prediction using PRS-PGx methods.

Authors:  Song Zhai; Hong Zhang; Devan V Mehrotra; Judong Shen
Journal:  Nat Commun       Date:  2022-09-08       Impact factor: 17.694

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.